Journal of Clinical Endocrinology & Metabolism, Vol 81, 1989-1993, Copyright © 1996 by Endocrine Society

ARTICLES

Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients

C Mestayer, I Berthaut, MC Portois, F Wright, F Kuttenn, I Mowszowicz and P Mauvais-Jarvis
Department of Endocrinology and Reproductive Medicine, Hopital Necker, Paris, France.

Dihydrotestosterone (DHT), the 5 alpha-reduced metabolite of testosterone, is the active molecule triggering androgen action, and 5 alpha-reductase (5 alpha-R), the enzyme converting testosterone to DHT, is a key step in this mechanism. Skin, like prostate, is a DHT- dependent tissue. Our laboratory demonstrated, many years ago, that 5 alpha-R in external genitalia was not regulated by androgens, whereas it was androgen dependent in public skin. As two genes, 5 alpha-R types 1 and 2, encoding for 5 alpha-R enzymes have been recently cloned, we undertook the present study to determine whether the two enzymes we had postulated on the basis of regulation studies were coincident with the cloned isoforms. The expression of the two isoforms was studied in genital and pubic skin fibroblasts from normal men, normal women, and hirsute patients. Messenger ribonucleic acid analysis, using Northern blot and RT-PCR techniques, indicated that both 5 alpha-R1 and -2 messenger ribonucleic acids are expressed in genital skin as well as in public skin fibroblasts. In contrast, studies using specific inhibitors of 5 alpha-R1 (LY306089) and 5 alpha-R2 (finasteride) showed that 5 alpha-R2 is predominant in pubic skin of normal men, normal women, and hirsute patients. These data raise the question of the possible use of specific 5 alpha-R1 inhibitors in the treatment of idiopathic hirsutism.

This article has been cited by other articles:

				M. O. Goodarzi, N. A. Shah, H. J. Antoine, M. Pall, X. Guo, and R. Azziz Variants in the 5{alpha}-Reductase Type 1 and Type 2 Genes Are Associated with Polycystic Ovary Syndrome and the Severity of Hirsutism in Affected Women J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4085 - 4091. [Abstract] [Full Text] [PDF]

				T. Raivio, L. Dunkel, S. Wickman, and O. A. Janne Serum Androgen Bioactivity in Adolescence: A Longitudinal Study of Boys with Constitutional Delay of Puberty J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1188 - 1192. [Abstract] [Full Text] [PDF]

				A. L. M. Boehmer, A. O. Brinkmann, R. M. Nijman, M. C. T. Verleun-Mooijman, P. de Ruiter, M. F. Niermeijer, and S. L. S. Drop Phenotypic Variation in a Family with Partial Androgen Insensitivity Syndrome Explained by Differences in 5{{alpha}} Dihydrotestosterone Availability J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1240 - 1246. [Abstract] [Full Text]

				L. Falsetti, A. Gambera, and G. Tisi Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome Hum. Reprod., January 1, 2001; 16(1): 36 - 42. [Abstract] [Full Text] [PDF]

				E. M Rocha, L A. Wickham, L. A da Silveira, K. L Krenzer, F.-S. Yu, I. Toda, B. D Sullivan, and D. A Sullivan Identification of androgen receptor protein and 5alpha -reductase mRNA in human ocular tissues Br. J. Ophthalmol., January 1, 2000; 84(1): 76 - 84. [Abstract] [Full Text]

				J. Bird, X. Li, Z. M. Lei, J. Sanfilippo, M. A. Yussman, and Ch. V. Rao Luteinizing Hormone and Human Chorionic Gonadotropin Decrease Type 2 5{alpha}-Reductase and Androgen Receptor Protein Levels in Women's Skin J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1776 - 1782. [Abstract] [Full Text]